Identification of prognostic biomarkers for patients with hepatocellular carcinoma after heptectomy

XIANGKUN WANG¹, XIWEN LIAO¹, CHENGKUN YANG¹, KETUAN HUANG¹, TINGDONG YU¹, LONG YU¹², CHUANGYE HAN¹, GUANGZHI ZHU¹, XIANMIN ZENG¹, ZHENGQIAN LIU¹, XIN ZHOU¹, WEI QIN¹, HAO SU¹, XINPING YE¹ and TAO PENG¹

¹Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021; ²Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, P.R. China

Received August 22, 2018; Accepted November 28, 2018

DOI: 10.3892/or.2019.6953

Abstract. Hepatocellular carcinoma (HCC) is a lethal malignancy with high morbidity and mortality rates worldwide. The identification of prognosis-associated biomarkers is crucial to improve HCC patient survival. The present study aimed to explore potential predictive biomarkers for HCC. Differentially expressed genes (DEGs) were analyzed in the GSE36376 dataset using GEO2R. Hub genes were identified and further investigated for prognostic value in HCC patients. A risk score model and nomogram were constructed to predict HCC prognosis and the nomogram visualized gene expression and clinical factors of probability for HCC prognosis. The majority of genes showed significant Pearson’s correlations with others (41 Pearson correlations P≤0.05, four Pearson correlations P>0.05). GO analysis revealed that terms such as ‘chemical carcinogenesis’ and ‘drug metabolism-cytochrome P450’ were enriched and may prove helpful to elucidate the mechanisms of hepatocarcinogenesis. Hub genes ADH4, CYP2C8, CYP2C9, CYP8B1, SLC22A1, TAT and HSD17B13 may be useful as predictive biomarkers for HCC prognosis.

Introduction

Liver cancer is more common in men than in women, and is the second leading cause of cancer-associated mortality worldwide in men living in less developed countries (1). It is estimated that ~50% of newly diagnosed cancer cases and mortalities globally occurred in China alone in 2012, which equates to approximately 391,250 new liver cancer cases and 372,750 mortalities (1). Hepatocellular carcinoma (HCC) accounts for the majority (70-90%) of primary liver cancer cases worldwide (2). Previous epidemiological surveys have revealed that chronic hepatitis B or C viral infection, cirrhosis, exposure to aflatoxin B1, obesity, chronic alcohol consumption and diabetes mellitus, as well as metabolic abnormalities including haemochromatosis and α1-antitrypsin deficiency, are common and significant risk factors for HCC development (3-5). Furthermore, recent studies indicate that approximately 1,000,000 new HCC cases are diagnosed each year worldwide, with the same incidence and morbidity rate, indicating that HCC diagnosis is typically at the advanced stage and prognosis remains poor (6,7). Despite advances in diagnosis, prevention and treatment, including ultrasonography, multiphase computerized tomography, magnetic resonance imaging, surgical resection, liver transplantation, transarterial chemoembolization, radiofrequency ablation and transarterial radiation, percutaneous ablation and...
systemic therapy, the prognosis for HCC patients remains unsatisfactory (8). The 5-year relative survival rate is approximately 7% (9). Therefore, identification of novel biomarkers for the early diagnosis of HCC is vital and may improve HCC prognosis.

At present, many reports have focused on the identification of prognosis-associated biomarkers. The role of astrocytic phosphoprotein PEA-15 in HCC has been evaluated and may be a novel target for HCC treatment, as well as a predictive biomarker for HCC patient prognosis (10). Furthermore, it has been suggested that CKLF-like MARVEL transmembrane domain-containing protein 5 may function as a tumor suppressor in human HCC and represent a valuable therapeutic target (11). microRNA (miR)-182-5p is recognized as a potential predictive biomarker for the early recurrence of HCC (12). Currently, DNA microarray approach has been used to investigate the genetic features of HCC in molecular biology (13). Accumulating evidence regarding gene expression in HCC has demonstrated that a variety of differentially expressed genes (DEGs) may be involved in the process of hepatocarcinogenesis (14). The combination of microarray techniques and bioinformatic analysis makes it conceivable to use DEGs in one or more chips to detect potential predictive biomarkers for several types of malignancies (15). Therefore, the present study focused on DEGs in microarrays and aimed to identify potential predictive biomarkers for patients with HCC.

Materials and methods

Data collection and processing. GEO2R (www.ncbi.nlm.nih.gov/geo/geo2r/) was initially used to identify DEGs in the GSE36376 gene expression profile in the Gene Expression Omnibus (GEO) database (16). The GSE36376 dataset (www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE36376) is embedded in the platform GPL10558 (Illumina HumanHT-12 v4 Expression Beadchip) and includes 240 tumor tissues and 193 adjacent non-tumor tissues of two gene expression by array sets: A training set and validation set (17).

Next, DEGs from the GSE36376 profile were acquired using the GEO2R tool with the criteria of log fold change=2 and P≤0.05. Furthermore, the Cytoscape software (version 3.6.0) plugin, CenTiScaPe (version 2.2), was employed to identify the top 10 hub genes in these DEGs on the basis of the following centralities: degree, betweenness and closeness (18).

Hub gene expression, survival and stratified analysis. The expression levels of 10 hub genes in multiple organs, as well as in tumor and non-tumor tissues were obtained from the GTEx portal (www.gtexportal.org/home) and the Gene Expression Profiling Interactive Analysis (GEPIA; gepia.cancer-pku.cn/index.html) server (19). Protein expression levels of the hub genes, clinical data with statistically significant P-values (≤0.05) were adjusted for further analysis to identify prognosis-associated genes. For the above identified genes, clinical data were stratified for further analysis.

Hub gene mutational and transcriptional analysis. The mutation status of hub genes using the cBioPortal website (www.cbioportal.org/) (21,22). Furthermore, transcripts per million (TPM) of the hub genes in liver tissues were analyzed to identify transcription levels at the log scale \[\log_2(\text{TPM}+1)\] using the GEPIA website (gepia.cancer-pku.cn/index.html) (19).

Construction of risk score model and nomogram. A risk score model was constructed based on the expression levels of prognosis-associated genes and the contribution coefficient (β) of the multivariate Cox proportional hazards regression model. The formula of the model was as follows: risk score=expression of gene\(_i\) x β\(_i\) of gene\(_i\) + expression of gene\(_j\) x β\(_j\) of gene\(_j\) + … + expression of gene\(_k\) x β\(_k\) of gene\(_k\). The risk score was then divided into high and low risk groups with the same cut-off criteria of gene expression. A Kaplan-Meier survival curve was drawn to predict patient survival. Prognostic receiver operating characteristic (ROC) curves were then created at 1-5 years.

A nomogram was also constructed based on seven prognosis-associated hub genes, clinical factors and tumor stage, to obtain patient survival at 1, 3 and 5 years. The contribution of each factor was limited to a maximum of 100 points.

Gene-gene and protein-protein interactions (PPI) network construction and functional enrichment analysis. To identify the biological processes and metabolic pathways of these hub genes, enrichment analysis of Gene Ontology (GO) was performed, including biological process (BP), cellular component (CC), and molecular function (MF), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways using The Database for Annotation, Visualization and Integrated Discovery (DAVID; david.ncifcrf.gov/) (15,23). In addition, visualized GO results were presented by the Cytoscape BinGO plugin version 3.6.0 (18,24). Gene-gene interaction networks were constructed using the GeneMANIA plugin (version 3.4.1) in Cytoscape software version 3.6.0 (25). The PPI network depicted interactions among these proteins and was constructed using the Search Tool for the Retrieval of Interacting Genes website (string-db.org/cgi/input.pl) (26).

Statistical analysis. Kaplan-Meier survival analysis by log rank test was used to calculate the median survival time (MST). Univariate and multivariate Cox proportional hazards models were used to calculate the hazard ratio (HR) and 95% confidence interval (CI). P≤0.05 was considered to indicate a statistically significant difference. Box plots by unpaired t-test, survival curves and ROC curves including area under the curve (AUC) were produced using GraphPad version 7.0 (GraphPad Software, Inc., La Jolla, CA, USA). Statistical analysis was performed using SPSS software version 16.0 (SPSS, Inc., Chicago, IL, USA).
Results

Processing of DEGs and hub genes. A total of 71 DEGs were obtained from the GSE36376 dataset and the top 10 hub genes were identified. These 10 hub genes included cytochrome P450 family 2 subfamily E member 1 (CYP2E1), cytochrome P450 family 2 subfamily A member 6 (CYP2A6), cytochrome P450 family 8 subfamily B member 1 (CYP8B1), cytochrome P450 family 2 subfamily C member 9 (CYP2C9), hydroxysteroid 11-β dehydrogenase 1 (HSD11B1), hydroxysteroid 17-β dehydrogenase 13 (HSD17B13), solute carrier family 22 member 1 (SLC22A1), cytochrome P450 family 2 subfamily C member 8 (CYP2C8), alcohol dehydrogenase 4 (class II), pi polypeptide (ADH4).

Analysis of hub gene expression, mutation and transcription. Hub gene expression in tumor tissues was downregulated compared with normal tissues in all cases (Fig. 1). However, only CYP2A6, CYP2C8, CYP2E1, HSD17B13 and SLC22A1 had a significant alteration in expression (P<0.05). Tissue expression data indicated that all of the hub genes were highly...
Jonathan expressed in liver tissue (Fig. 2). Mutation analysis of hub genes revealed that mutations were present in different ratios (Fig. 3A). At 11%, \textit{HSD11B1} was the most significant in terms of mutation ratio, of which the majority were amplification mutations. Transcriptional analysis (Fig. 3B) demonstrated that all hub genes were differentially transcribed in tumor and normal tissues. Furthermore, normal tissues had consistently high TPM in the 10 hub genes. Detailed results are shown in Fig. 3.

Protein expression data indicated that eight proteins were highly expressed in liver tissue, excluding \textit{TAT} and \textit{CYP8B1}
Figure 3. Mutational and transcriptional analysis of hub genes. (A) Mutational analysis including missense mutation, deep deletion and amplification of the 10 hub genes. (B) Transcriptional analyses (TPM) of the 10 hub genes in tumor and normal tissues. TPM, transcripts per million; CYP2E1, cytochrome P450 family 2 subfamily E member 1; TAT, tyrosine aminotransferase; CYP2A6, cytochrome P450 family 2 subfamily A member 6; CYP8B1, cytochrome P450 family 8 subfamily B member 1; CYP2C9, cytochrome P450 family 2 subfamily C member 9; HSD11B1, hydroxysteroid 11-β dehydrogenase 1; HSD17B13, hydroxysteroid 17-β dehydrogenase 13; SLC22A1, solute carrier family 22 member 1; CYP2C8, cytochrome P450 family 2 subfamily C member 8; ADH4, alcohol dehydrogenase 4 (class II), pi polypeptide.

Figure 4. Immunohistochemistry results of protein expression levels of hub genes ADH4, CYP2A6, CYP2C8, CYP2C9, CYP2E1, HSD11B1, HSD17B13 and SLC22A1 in normal liver tissues. ADH4, alcohol dehydrogenase 4 (class II), pi polypeptide; CYP2A6, cytochrome P450 family 2 subfamily A member 6; CYP2C8, cytochrome P450 family 2 subfamily C member 8; CYP2C9, cytochrome P450 family 2 subfamily C member 9; CYP2E1, cytochrome P450 family 2 subfamily E member 1; HSD11B1, hydroxysteroid 11-β dehydrogenase 1; HSD17B13, hydroxysteroid 17-β dehydrogenase 13; SLC22A1, solute carrier family 22 member 1.
Table II. Demographic characteristics of HCC patients.

| Variables                | Patients (n=360) | Number (%) | MST (days) | HR (95% CI)        | Log-rank P-value |
|--------------------------|------------------|------------|------------|-------------------|-----------------|
| Race                     |                  |            |            |                   |                 |
| Asian                    | 155              | 44 (28.4)  | NA         |                   |                 |
| Non-Asian                | 196              | 78 (39.8)  | 1,397      | 1.29 (0.89-1.87)  | 0.184           |
| Sex                      |                  |            |            |                   |                 |
| Male                     | 244              | 78 (32.0)  | 2,486      |                   |                 |
| Female                   | 116              | 48 (41.4)  | 1,560      | 1.21 (0.84-1.73)  | 0.308           |
| Age (years)              |                  |            |            |                   |                 |
| ≤61                      | 186              | 59 (31.7)  | 2,116      |                   |                 |
| >61                      | 171              | 65 (38.0)  | 1,622      | 1.18 (0.83-1.69)  | 0.349           |
| Tumor stage              |                  |            |            |                   |                 |
| I and II                 | 252              | 66 (26.2)  | 2,532      |                   |                 |
| III and IV               | 87               | 48 (55.2)  | 770        | 2.50 (1.72-3.63)  | <0.0001         |

Data were unavailable for race in 9 patients, age in 3 patients and tumor stage in 21 patients. MST, median survival time; HR, hazard ratio; CI, confidence interval; NA, not available; Ref., reference; Tumor stage was determined with the Tumor, Node and Metastasis staging system version 7.

Figure 5. Kaplan-Meier plots of hub genes ADH4, CYP2A6, CYP2C6, CYP2C9, CYP2E1, CYP8B1, HSD11B1, HSD17B13, SLC22A1 and TAT. CYP2E1, cytochrome P450 family 2 subfamily E member 1; TAT, tyrosine aminotransferase; CYP2A6, cytochrome P450 family 2 subfamily A member 6; CYP8B1, cytochrome P450 family 8 subfamily B member 1; CYP2C9, cytochrome P450 family 2 subfamily C member 9; HSD11B1, hydroxysteroid 11-β dehydrogenase 1; HSD17B13, hydroxysteroid 17-β dehydrogenase 13; SLC22A1, solute carrier family 22 member 1; CYP2C8, cytochrome p450 family 2 subfamily C member 8; ADH4, alcohol dehydrogenase 4 (class II), pi polypeptide.
Demographic and clinicopathological characteristics. A total of 360 HCC patients were included in the dataset. Survival analysis indicated that tumor stage showed statistical significance (log-rank P<0.0001), but all other factors were not significant (log-rank P>0.05; Table II).

Expression levels and survival analysis of hub genes. In the univariate survival analysis, ADH4, CYP2C8, CYP2C9, CYP2E1, CYP8B1, HSD17B13, SLC22A1 and TAT were significant (P<0.05; Table III and Fig. 5). Following adjustment for tumor stage, ADH4, CYP2C8, CYP2C9, CYP8B1, SLC22A1, TAT and HSD17B13 were significant (P<0.05; Table III) while CYP2A6, CYP2E1, HSD11B1 were not significant (P>0.05). All hub genes were significantly different when comparing high and low expression levels (P<0.0001; Fig. 6A).

Stratified analysis of prognosis-associated genes. In the stratification of tumor stage, high expression levels of CYP2C8, CYP2C9, SLC22A1, TAT and HSD17B13 had tumor suppressor effects and were significant (P<0.05). The other genes did not show any significant effects (P>0.05).

Table III. Survival analysis of HCC patient prognosis.

| Gene expression | Patients/events | MST (days) | Crude HR (95% CI) | Crude P-value | Adjusted HR (95% CI) | Adjusted P-value |
|-----------------|----------------|-----------|------------------|--------------|---------------------|-----------------|
| ADH4            |                |           |                  |              |                     |                 |
| Low             | 180/80         | 1,372     | Ref.             |              | Ref.                |                 |
| High            | 180/46         | 2,456     | 0.52 (0.36-0.75) | <0.001*      | 0.55 (0.38-0.81)    | 0.002*          |
| CYP2A6          |                |           |                  |              |                     |                 |
| Low             | 180/66         | 1,694     | Ref.             |              | Ref.                |                 |
| High            | 180/60         | 1,791     | 0.83 (0.58-1.18) | 0.291        | 0.83 (0.57-1.20)    | 0.321           |
| CYP2C8          |                |           |                  |              |                     |                 |
| Low             | 180/75         | 1,229     | Ref.             |              | Ref.                |                 |
| High            | 180/51         | 2,456     | 0.56 (0.39-0.79) | 0.001*       | 0.56 (0.38-0.83)    | 0.003*          |
| CYP2C9          |                |           |                  |              |                     |                 |
| Low             | 180/74         | 1,271     | Ref.             |              | Ref.                |                 |
| High            | 180/52         | 2,456     | 0.56 (0.39-0.80) | 0.001*       | 0.64 (0.43-0.93)    | 0.020*          |
| CYP2E1          |                |           |                  |              |                     |                 |
| Low             | 180/75         | 1,490     | Ref.             |              | Ref.                |                 |
| High            | 180/51         | 2,456     | 0.67 (0.47-0.96) | 0.029*       | 0.74 (0.51-1.08)    | 0.119           |
| CYP8B1          |                |           |                  |              |                     |                 |
| Low             | 180/73         | 1,372     | Ref.             |              | Ref.                |                 |
| High            | 180/53         | 2,131     | 0.63 (0.44-0.90) | 0.010*       | 0.61 (0.42-0.89)    | 0.011*          |
| HSD11B1         |                |           |                  |              |                     |                 |
| Low             | 180/71         | 1,397     | Ref.             |              | Ref.                |                 |
| High            | 180/55         | 2,131     | 0.77 (0.54-1.09) | 0.142        | 0.81 (0.56-1.18)    | 0.279           |
| SLC22A1         |                |           |                  |              |                     |                 |
| Low             | 180/79         | 1,149     | Ref.             |              | Ref.                |                 |
| High            | 180/47         | 2,456     | 0.49 (0.34-0.70) | <0.0001*     | 0.51 (0.35-0.75)    | 0.001*          |
| TAT             |                |           |                  |              |                     |                 |
| Low             | 180/74         | 1,372     | Ref.             |              | Ref.                |                 |
| High            | 180/52         | 2,131     | 0.56 (0.39-0.80) | 0.001*       | 0.53 (0.36-0.78)    | 0.001*          |
| HSD17B13        |                |           |                  |              |                     |                 |
| Low             | 180/74         | 1,372     | Ref.             |              | Ref.                |                 |
| High            | 180/52         | 2,456     | 0.57 (0.40-0.81) | 0.001*       | 0.56 (0.39-0.82)    | 0.003*          |

*P<0.05. MST, median survival time; HR, hazard ratio; CI, confidence interval; CYP2E1, cytochrome P450 family 2 subfamily E member 1; TAT, tyrosine aminotransferase; CYP2A6, cytochrome P450 family 2 subfamily A member 6; CYP8B1, cytochrome P450 family 8 subfamily B member 1; CYP2C9, cytochrome P450 family 2 subfamily C member 9; HSD11B1, hydroxysteroid 11-β dehydrogenase 1; HSD17B13, hydroxysteroid 17-β dehydrogenase 13; SLC22A1, solute carrier family 22 member 21 member 1; CYP2C8, cytochrome p450 family 2 subfamily C member 8; ADH4, alcohol dehydrogenase 4 (class II), pi polypeptide.

(data not shown; Fig. 4), which was similar to the tissue expression results.
Table IV. Stratified analysis of *HSD17B13*, *SLC22A1* and *TAT* for HCC patients (n=360) in terms of prognosis.

| Characteristics   | HSD17B13   | SLC22A1   | TAT          |
|-------------------|------------|-----------|--------------|
|                   | Low (95% CI) | High (95% CI) | P-value  | Low (95% CI) | High (95% CI) | P-value  | Low (95% CI) | High (95% CI) | P-value  |
| Race              |            |           |             |            |           |             |            |           |             |            |
| Asian             | 87 (0.24-0.93) | 68 (0.24-0.93) | 0.03<sup>a</sup> | 88 (0.15-0.68) | 67 (0.15-0.68) | 0.003<sup>a</sup> | 92 (0.19-0.78) | 63 (0.19-0.78) | 0.009<sup>a</sup> |
| Non-Asian         | 89 (0.34-0.89) | 107 (0.34-0.89) | 0.014<sup>a</sup> | 89 (0.40-1.05) | 107 (0.40-1.05) | 0.076 | 82 (0.41-1.07) | 114 (0.41-1.07) | 0.092 |
| Sex               |            |           |             |            |           |             |            |           |             |            |
| Male              | 128 (0.28-0.78) | 116 (0.28-0.78) | 0.003<sup>a</sup> | 111 (0.29-0.79) | 133 (0.29-0.79) | 0.004<sup>a</sup> | 115 (0.27-0.72) | 129 (0.27-0.72) | 0.001<sup>a</sup> |
| Female            | 52 (0.39-1.28) | 64 (0.39-1.28) | 0.258 | 69 (0.31-1.13) | 47 (0.31-1.13) | 0.113 | 65 (0.43-1.45) | 51 (0.43-1.45) | 0.45 |
| Age (years)       |            |           |             |            |           |             |            |           |             |            |
| <61               | 100 (0.24-0.74) | 86 (0.24-0.74) | 0.003<sup>a</sup> | 104 (0.16-0.55) | 82 (0.16-0.55) | <0.001<sup>a</sup> | 103 (0.21-0.67) | 83 (0.21-0.67) | 0.001<sup>a</sup> |
| >61               | 80 (0.39-1.12) | 91 (0.39-1.12) | 0.121 | 74 (0.45-1.31) | 97 (0.45-1.31) | 0.325 | 74 (0.43-1.24) | 97 (0.43-1.24) | 0.244 |
| Tumor stage       |            |           |             |            |           |             |            |           |             |            |
| I and II          | 121 (0.37-0.99) | 131 (0.37-0.99) | 0.047<sup>a</sup> | 116 (0.34-0.91) | 136 (0.34-0.91) | 0.019<sup>a</sup> | 121 (0.37-1.00) | 131 (0.37-1.00) | 0.048<sup>a</sup> |
| III and IV        | 50 (0.26-0.86) | 37 (0.26-0.86) | 0.015<sup>a</sup> | 58 (0.20-0.79) | 29 (0.20-0.79) | 0.009<sup>a</sup> | 53 (0.21-0.77) | 34 (0.21-0.77) | 0.006<sup>a</sup> |

Data were unavailable for race in 9 patients, age in 3 patients and tumor stage in 21 patients. Tumor stage was determined with the Tumor, Node and Metastasis staging system version 7. *P<0.05. HR, hazard ratio; 95% CI, 95% confidence interval.
Table V. Stratified analysis of ADH4, CYP2C8, CYP2C9 and CYP8B1 for HCC patients (n=360) in terms of prognosis.

| Characteristics | ADH4 | CYP2C8 | CYP2C9 | CYP8B1 |
|-----------------|------|--------|--------|--------|
|                 | Low  | High   | Adjusted HR (95% CI) | P-value | Low  | High   | Adjusted HR (95% CI) | P-value | Low  | High   | Adjusted HR (95% CI) | P-value | Low  | High   | Adjusted HR (95% CI) | P-value |
| Race            |      |        | Adjusted P-value |        |      |        | Adjusted P-value |        |      |        | Adjusted P-value |        |      |        | Adjusted P-value |        |
| Asian           | 91   | 64     | 0.35 (0.17-0.74) | 0.005a | 85   | 70     | 0.40 (0.20-0.80) | 0.009a | 79   | 76     | 0.40 (0.21-0.75) | 0.004a | 93   | 62     | 0.28 (0.13-0.59) | 0.001a |
| Non-Asian       | 85   | 111    | 0.62 (0.38-1.01) | 0.057  | 92   | 104    | 0.70 (0.43-1.13) | 0.143  | 97   | 99     | 0.75 (0.45-1.23) | 0.251  | 84   | 112    | 0.90 (0.55-1.45) | 0.658  |
| Sex             |      |        |                   |        |      |        |                   |        |      |        |                   |        |      |        |                   |        |
| Male            | 107  | 137    | 0.51 (0.31-0.83) | 0.006a | 120  | 124    | 0.48 (0.29-0.80) | 0.005a | 108  | 136    | 0.54 (0.33-0.89) | 0.015a | 109  | 135    | 0.48 (0.30-0.78) | 0.003a |
| Female          | 73   | 43     | 0.65 (0.34-1.25) | 0.196  | 60   | 56     | 0.75 (0.42-1.37) | 0.355  | 72   | 44     | 0.85 (0.46-1.58) | 0.613  | 71   | 45     | 1.00 (0.54-1.85) | 0.998  |
| Age (years)     |      |        |                   |        |      |        |                   |        |      |        |                   |        |      |        |                   |        |
| ≤61             | 103  | 83     | 0.43 (0.24-0.77) | 0.005a | 106  | 80     | 0.54 (0.30-0.98) | 0.044a | 98   | 88     | 0.73 (0.42-1.27) | 0.269  | 115  | 71     | 0.27 (0.14-0.53) | <0.001a |
| >61             | 75   | 96     | 0.63 (0.36-1.09) | 0.096  | 71   | 100    | 0.63 (0.37-1.06) | 0.08   | 79   | 92     | 0.62 (0.37-1.06) | 0.082  | 63   | 108    | 0.99 (0.58-1.69) | 0.973  |
| Tumor stage     |      |        |                   |        |      |        |                   |        |      |        |                   |        |      |        |                   |        |
| I and II        | 117  | 135    | 0.62 (0.38-1.01) | 0.055  | 113  | 139    | 0.58 (0.36-0.95) | 0.029a | 113  | 139    | 0.61 (0.38-1.00) | 0.048a | 121  | 131    | 0.79 (0.48-1.28) | 0.334  |
| III and IV      | 53   | 34     | 0.45 (0.24-0.84) | 0.013a | 59   | 28     | 0.50 (0.27-0.95) | 0.033a | 56   | 31     | 0.65 (0.35-1.20) | 0.171  | 51   | 36     | 0.38 (0.20-0.71) | 0.003a |

Data were unavailable for race in 9 patients, age in 3 patients and tumor stage in 21 patients. Tumor stage was determined with the Tumor, Node and Metastasis staging system version 7. *P<0.05. HR, hazard ratio; 95% CI, 95% confidence interval.
roles in stages I and II (P≤0.05) while high expression levels of ADH4, CYP2C8, CYP8B1, SLC22A1, TAT and HSD17B13 had tumor suppressor roles in stages III and IV (P≤0.05). Detailed results are presented in Tables IV and V.

**Hub gene co-expression and Pearson correlation analysis.** The majority of hub genes showed significant Pearson correlations with other genes. For example, CYP2E1 was positively correlated with CYP2C8, CYP2C9, CYP8B1, ADH4 and HSD11B1, and negatively correlated with CYP2A6 and HSD17B13. Detailed results are presented in Fig. 6B.

In the PPI network, most of the hub genes exhibited complicated interactive co-expression relationships, with the exception of HSD11B1, which was co-expressed with HSD17B13 alone (Fig. 6C). In the gene-gene interaction network, each gene was co-expressed with at least two other genes (Fig. 6D).

**Risk score model and nomogram construction.** A risk score model was constructed using the aforementioned formula, which contained risk score ranking, survival status and heat maps of gene expressions (Fig. 7A). The Kaplan-Meier plot revealed that the percent survival difference between the low and high risk groups was significant (Fig. 7B). ROC curves were then constructed to evaluate the prognostic values of the model. In the 1-5 year ROC curves, all AUCs were above 0.6 (Fig. 7C), which shows that this model was useful for prognosis prediction. In the comparison of high and low risk score groups, all of the comparisons showed significant P-values (all P<0.001; Fig. 7D).
The contributions of each factor were present in the nomogram (Fig. 8). In detail, tumor stages III and IV showed the maximum 100 points. Unlike the other genes, high expression levels of \textit{CYP8B1} had a high number of points. High points typically indicated low survival probability at 1, 3 and 5 years. As expected, there was a high probability of survival prediction at 1 year compared with 5 years.

**Hub genes enrichment analysis.** GO analysis revealed that genes were significantly enriched in the terms such as ‘oxidation-reduction process’, the ‘epoxyxygenase P450 pathway’, ‘metabolism of xenobiotics by cytochrome P450’, ‘chemical carcinogenesis’, ‘drug metabolic processes’ and ‘organelle membranes’ (Fig. 9).

BP terms, including ‘exogenous drug catabolic process’, ‘drug catabolic process’, ‘secondary metabolic process’ and ‘oxidation reduction’, were significantly enriched (Fig. 10). In CC terms, ‘subsynaptic reticulum’, ‘endoplasmic reticulum’, ‘microsome’ and ‘vesicular fraction’, were enriched (Fig. 11). ‘Oxygen binding’, ‘iron ion binding’, ‘heme binding’, ‘electron carrier activity’ and ‘oxidoreductase activity’, were enriched in terms of MF (Fig. 12).

**Discussion**

In the present study, DEGs were analyzed in microarrays to identify hub genes. The top 10 hub genes in the GSE36376 dataset were examined for their prognostic prediction value in HCC. A total of seven genes, including \textit{ADH4}, \textit{CYP2C8}, \textit{CYP2C9}, \textit{CYP8B1}, \textit{SLC22A1}, \textit{TAT} and \textit{HSD17B13}, were identified as potential prognostic biomarkers. In addition, high expression levels of these hub genes were associated with tumor suppressing roles in HCC. Stratified analysis of clinical factors further revealed their prognostic values in subgroups.
A risk score model for patient survival was constructed and evaluated, which confirmed its value for assessing prognosis. A nomogram was created to identify the degree of the contribution made by each factor. Enrichment analysis of the hub genes highlighted the metabolic pathways and biological processes that the hub genes were involved in, which may provide clues into the exact mechanisms of HCC development.

Valuable data in gene microarrays may be lost due to potentially unpredictable problems with the samples when the results of a single piece of research are analyzed (27). Furthermore, using a Student’s t-test to analyze microarray data has several limitations (27). Small sample sizes may lead to unreliable variance estimation, leading to a high false-positive rate, while some significant and reliable differences in expression may be missed (28). However, in the present study, analyzing microarray data from a study with a large sample size, allowed the acquisition of potentially useful information for further analysis. In total, 433 samples from the GSE36376 dataset were analyzed to obtain DEGs, in order to determine potential serum biomarkers for HCC diagnosis and prognosis. Focused on an Asian population, the present study also searched for DEGs using the GEO2R online resource. The top 10 hub genes in these DEGs were selected for further analysis, and seven of these hub genes, \textit{ADH4}, \textit{CYP2C8}, \textit{CYP2C9}, \textit{CYP2C9}, \textit{SLC22A1}, \textit{TAT}, and \textit{HSD17B13}, were confirmed to have prognostic value in HCC.
The human ADH4 enzyme is encoded by the ADH4 gene, which maps to 4q22 within the ADH gene cluster (29). Previous studies have revealed that a ADH4 gene variant confers risk for alcohol dependence (AD) and related traits in European Americans and African Americans (29). Edenberg et al (30) reported that 16 single nucleotide polymorphisms (SNP) of ADH4, including rs2226896, are associated with AD, in an independent collaborative study on the genetics of alcoholism. Edenberg et al (31) showed that ADH4 promoter variant -75A/C (rs800759), which could alter ADH4 enzyme expression levels significantly, as well as the 159A/G variant were significantly linked to AD in European Americans and African Americans in a Brazilian population (31). Previous studies have reported that ADH4 may be associated with cluster headaches and personality traits such as agreeableness and extraversion (32,33). In addition, polymorphisms in the ADH4 gene are associated with a decreased risk of ovarian cancer (34) and an increased risk of upper aerodigestive tract cancer (35), which suggests that the ADH4 may be involved in tumorigenesis. Wei et al (36) found that ADH4 mRNA expression in HCC is significantly lower than that in non-cancerous tissue, and ADH4 protein expression is also reduced in HCC, which indicates that ADH4 may serve as a tumor suppressor. These findings are consistent with the results of the present study, where ADH4 was identified as a potential prognostic biomarker for HCC.

The CYP2 family contains many subfamilies, including CYP2A, CYP2B, CYP2C, CYP2D, CYP2E and CYP2F (37). CYP2C8 and CYP2C9 are members of the CYP2C subfamily that are localized in a single gene locus on chromosome 10 (38,39). CYP2C8 shares sequence homology with CYP2C9, that metabolizes several drugs including analgesics (40), antidiabetic and cholesterol-lowering drugs (41). CYP2C9 metabolizes the majority of angiotensin II type 1 receptor blockers (42) and neurological drugs (43). In addition, CYP2C8 has been associated with an increased risk of essential hypertension and coronary artery disease in Bulgarian patients (44), anemia (45), vascular inflammatory disease (46).
and breast cancer (47). It has been reported that CYP2C9 downregulation by miR-128-3p is associated with HCC (48). In addition, we have previously reported that analysis of CYP2C8 and CYP2C9 expression in combination is better than analyzing them in isolation (37).

CYP8B1 is predominantly expressed in hepatocytes in a homogenous pattern (49) and is involved in bile acid synthesis of bile acids (50). Overexpression of CYP8B1 alone or in combination with CYP7A1, but not of CYP7A1 alone, reverses obeticholic acid-induced alterations in bile acid levels (taurocholic acid), bile acid composition (taurocholic acid and α/β-muricholic acids) and cholesterol absorption (51). The SNP rs3732860 in the 3'-untranslated region of the CYP8B1 gene is linked to gallstone disease risk in the Chinese Han population (52,53). However, the function of CYP8B1 in cancer remains elusive. The present study indicated that CYP8B1 may serve as a potential biomarker for HCC, and may be involved in tumor initiation and development.

SLC22A1 has the ability to encode solute carrier family 22 member 1, which is not only an uptake transporter but also has a predictive value for the molecular response to imatinib mesylate therapy (54). Patients who experience a major molecular response have higher SLC22A1 expression compared with those without a major molecular response (55). SLC22A1-ABCB1 haplotype profiles can predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia (56). Indirect SLC22A1 gene upregulation by dexamethasone may be caused by glucocorticoid receptor-induced hepatocyte nuclear factor-4α expression in primary human hepatocytes, but not in hepatocyte-derived tumor cell lines (57). HCC and cholangiocarcinoma development is typically accompanied by decreased SLC22A1 expression, which may significantly alter the ability of sorafenib to reach active intracellular concentrations in these tumors (58). Downregulated SLC22A1 expression is associated with tumor progression and decreased survival in patients with cholangiocarcinoma (59). However, to the best of our knowledge, the relationship between SLC22A1 and HCC patient prognosis has not been reported. The present study demonstrated that SLC22A1 may be a predictive biomarker for HCC.

TAT is associated with the catalyzing the transamination of tyrosine and other aromatic amino acids and plays a role in recovery from tyrosinemia type II, hepatitis and hepatic carcinoma (60). Deficiency of TAT causes marked hypertyrosinemia, which leads to painful palmoplantar hyperkeratosis, pseudodendritic keratitis, and variable mental retardation (61). Recurrent mutation of the TAT gene has been reported in those
affected by Richner-Hanhart syndrome (62). Fu et al (63) reported that downregulation of TAT at a frequently deleted region, 16q22, contributes to the pathogenesis of HCC, and it was demonstrated that TAT is a novel tumor suppressor gene. This finding is consistent with the results of the present study, and may be used as an effective serum biomarker for HCC.

Su et al (64) reported that HSD17B13 is upregulated in the livers of patients with non-alcoholic fatty liver disease. HSD17B13 expression is localized to liquid droplets (65). In addition, Chen et al (66) reported that HSD17B13 is downregulated in HCC, and has a tumor suppressor role via inhibition of HCC progression and recurrence (66). This finding is in accordance with the results of the present study, where it was concluded that HSD17B13 may serve as a potential predictive biomarker for HCC.

In regards to metabolic pathways, our previous study demonstrated that the CYP2C subfamily members are involved in chemical carcinogenesis (37). The formation of DNA adducts, dG-C8-IQ, dG-N-IQ, dG-C8-MelQx and dG-N-MelQx, may induce liver, colon lung and breast cancer tumorigenesis (37). The present study found that the identified hub genes were also enriched in chemical carcinogenesis. Additionally, gene were enriched in ‘drug metabolism-cytochrome P450’, ‘metabolism of xenobiotics by cytochrome P450’, ‘retinol metabolism’, ‘linoleic acid metabolism’, ‘arachidonic acid metabolism’, ‘tyrosine metabolism’, and ‘steroid hormone biosynthesis’. These metabolic processes and pathways provide evidence that the hub genes may be involved in hepatocarcinogenesis.

There are some limitations to the present study. First, larger samples that include other populations are required to validate the findings of the present study. Second, an increased number of valid clinical factors, such as race, drinking status, smoking status, cirrhosis, Barcelona-Clinic Liver cancer staging, hepatitis infection status, antiviral therapy, α-fetoprotein levels and microvascular invasion, should be included in the analysis. Third, functional validation in a well-designed clinical trial is required to examine the biological behavior of prognosis-associated genes on HCC initiation and progression. As the present study explored the potential prognostic biomarkers for HCC, the identification and clinical significance of targeted drugs was not investigated in the present study. Thus, it is crucial to focus future studies on these topics.

The present study indicated that low gene expression of ADH4, CYP2C8, CYP2C9, CYP8B1, SLC22A1, TAT and HSD17B13 are predictors of poor prognosis in HCC. Further functional trials and identification of targeted drugs for these hub genes is warranted to determine clinical application. In detail, trials in vivo and in vitro should be conducted to explore biological behavior, such as invasion, metastasis and proliferation ability. Then, the influence potential drugs on their target genes should be validated, to determine whether targeted overexpression of these genes improve HCC prognosis.

Acknowledgements

The authors would like to acknowledge the laboratory equipment and platform support provided by the Key Laboratory of Early Prevention and Treatment for Regional High-Incidence-Tumor (Guangxi Medical University; Ministry of Education, Nanning, China). The authors would also like to acknowledge the helpful comments on this article received from our reviewers.

Funding

The present study was supported in part by the National Nature Science Foundation of China (grant nos. 81560535, 81072321, 30760243, 30460143 and 30560133), the 2009 Program for New Century Excellent Talents in University, Guangxi Nature Sciences Foundation (grant no. GuiKeGong 1104003A-7), the Guangxi Health Ministry Medicine Grant (grant no. Key-Scientific Research-Grant Z201018), the Self-Raised Scientific Research Fund of the Health and Family Planning Commission of Guangxi Zhuang Autonomous Region (grant no. Z2016318), the Basic Ability Improvement Project for Middle-aged and Young Teachers in Guangxi Colleges and Universities (grant no. 2018KY0110), Innovation Project of Guangxi Graduate Education (grant no. JGY2018037) and the Research Institute of Innovative Think-tank in Guangxi Medical University (The gene-environment interaction in hepatocarcinogenesis in Guangxi HCCs and its translational applications in the HCC prevention).

Availability of data and materials

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

XW and TP designed the study. XL, CY, TY, LY, CH, XZe, ZL, XZh, WQ, HS, XY and TP conducted the study and analyzed the data. XW wrote the manuscript and TP revised the manuscript. All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.
2. Kolonel LN and Wilkens LR: Migrant studies. In: Cancer Epide- miology and Prevention. Schottenfeld D and Fraumeni JF, Jr (eds). 3rd edition. Oxford University Press, Inc., New York, NY, pp189-201, 2006.
3. Kgatle MM, Setsheki M and Hairwadzi HN: Hepatoepigenetic alterations in viral and nonviral-induced hepatocellular carci- noma. Biomed Res Int 2016: 3956485, 2016.
14. Marotta F, Vangieri B, Cecere A and Gattoni A: The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect. Clin Ter 155: 187-199, 2004.

15. Coleman WB: Mechanisms of human hepatocarcinogenesis. Cancer Med 4: 573-588, 2003.

16. Dominguez-Malagón H and Gaytan-Graham S: Hepatocellular carcinoma: An update. Ultrastruct Pathol 25: 497-516, 2001.

17. Chen G, Wang D, Zhao X, Cao J, Zhao Y, Wang F, Bai J, Luo D and Li L: miR-135-5p modulates malignant behaviors of hepatocellular carcinoma cells through direct regulation of XPC and indirectly regulating GSK-3β-involved Wnt/β-catenin signaling. Cancer Cell Int 17: 118, 2017.

18. Balogh J, Victor D III, Asham EH, Burroughs SG, Boktor M, Saharìa À, Li X, Ghobrial RM and Monsour HP Jr: Hepatocellular carcinoma: A review. J Hepatocell Carcinoma 3: 41-53, 2016.

19. Tien AJ, Chien CY, Chen YH, Lin LC and Chien CT: Fruitings bodies of antrodia cinnamomea and its active triterpenoid, antcin A, induce anticancer activities, fibrosis and carcinogenesis in rats. Am J Chin Med 43: 173-198, 2015.

20. Quintavalle C, Hindupur SK, Quagliata L, Pallante P, Nigro C, Condorelli G, Andersen JB, Taggersche KE, Roh W, Beguniot F, et al: Phosphoprotein enriched in diabetes (PEPD/PEA15) promotes migration in hepatocellular carcinoma and confers resistance to sorafenib. Cell Cycle 17, 2017.

21. Xu G and Dang C: CMTM5 is downregulated and suppresses tumour growth in hepatocellular carcinoma through regulating PI3K-AKT signalling. Cancer Cell Int 17: 113, 2017.

22. Cao MQ, You AB, Zhu XD, Zheng W, Zhang YY, Zhang SZ, Zhang KW, Cai H, Shi WK, Li XL, et al: miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a. J Hematol Oncol 11: 12, 2018.

23. Maes T, Sfakianakis I, Staib F, Krupp M, Galle PR and Teufel A: Huang da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of complex cancer genomics and clinical profiles using the cBioCancerGenomicsPortal: A model of metabolic integration, fibrosis and carcinogenesis in rats. Am J Chin Med 45: 173-198, 2017.

24. Davis S and Meltzer PS: GEOquery: A bridge between the gene expression omnibus (GEO) and BiConductor. Bioinformatics 23: 1846-1847, 2007.

25. Lim HY, Sohn I, Deng S, Lee J, Jung SH, Deng S, Lee J, Wang K, Tien AJ, Chien CY, Heuer ML, Larsson E, et al: Pharmacogenomics of complex cancer genomics and clinical profiles using the cBioCancerGenomicsPortal: A model of metabolic integration, fibrosis and carcinogenesis in rats. Am J Chin Med 46: 353-372, 2018.

26. Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al: The STRING database in 2017: Quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res 45: D362-D368, 2017.

27. Lu X, Sun W, Tang Y, Zhu L, Li Y, Ou C, Yang C, Su J, Luo C, Hu Y and Cao J: Identification of key genes in hepatocellular carcinoma and validation of the candidate gene, cdc25a, using gene set enrichment analysis, meta-analysis and cross-species comparisons. Mol Med 20: 117-128, 2016.

28. MacDonald JW and Ghosh D: COPA-cancer outlier profile analysis. Bioinformatics 22: 2950-2951, 2006.

29. Luo X, Zuo L, Kranzler HR, Wang S, Anton RF and Gerlenter J: Recent genetic model of an ADH4 variant in substance dependence in African-Americans: A model of utility of theHWI Test. Behav Brain Test 4: 42, 2008.

30. Edenberg HJ, Xuei X, Chen JH, Tian H, Wetherill LF, Dick DM, Almasy L, Bierut L, Bucholz KK, Goate A, et al: Association of alcohol dehydrogenase genes with alcohol dependence: a comprehensive analysis. Hum Mol Genet 15: 1539-1549, 2006.

31. Edenberg HJ, Jerome RE and Li M: Polymorphism of the human alcohol dehydrogenase 4 (ADH4) promoter affects gene expression. Pharmacogenetics 9: 25-30, 1999.

32. Guindalini C, Scivoletto S, Ferreira RM, Brem G, Zillbirm M, Peluso MA and Zatz M: Association of genetic variants in alcohol dehydrogenase 4 with alcohol dependence in Brazilian patients. Am J Psychiatry 162: 1005-1007, 2005.

33. Edenberg HJ, Xuei X, Chen JH, Tian H, Wetherill LF, Dick DM, Almasy L, Bierut L, Bucholz KK, Goate A, et al: Association of alcohol dehydrogenase genes with alcohol dependence in Brazilian patients. Am J Psychiatry 162: 1005-1007, 2005.

34. Goede EL, White KL, Vierkant RA, Phelan CM, Cunningham JM, Schildkraut JM, Berchuck A, Larson MC, Fredly BL, Olson JE, et al: Xenobiotic-metabolizing gene polymorphisms and ovarian cancer risk. Mol Carcinog 50: 1002, 2011.

35. Oze I, Matsu K, Suzuki T, Kawase T, Watanabe M, Hiraki A, Ito H, Hosono S, Ozawa T, Hataoka S, et al: Impact of multiple alcohol dehydrogenase gene polymorphisms on risk of upper aerodigestive tract cancers in a Japanese population. Cancer Epidemiol Biomarkers Prev 18: 3097-3102, 2009.

36. Wei RR, Zang MY, Rao HL, Pu HY, Zhang HZ and Wang HY: Identification of ADH4 as a novel and potential prognostic marker in hepatocellular carcinoma. Med Oncol 29: 2737-2743, 2012.

37. Wang X, Yu T, Liao X, Yang C, Han C, Zhu G, Huang K, Yu L, Qin W, Su H, et al: The prognostic value of CYP2C subfamily genes in hepatocellular carcinoma. Cancer Med 7: 966-980, 2018.

38. Gelboin HV and Krausk P: Monoclonal antibodies and multifunctional cytochrome P450: Drug metabolism as paradigm. J Clin Pharmacol 46: 353-372, 2006.

39. Goldstein JA and de Morais SM: Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4: 285-299, 1994.

40. Hamman MA, Thompson GA and Hall SD: Regionselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C9. Biochem Pharmacol 68: 312-325, 2004.

41. Chang TK: Contribution of CYP2C9, CYP2A6, and CYP2B6 to the metabolism of ibuprofen and its active metabolites. J Clin Pharmacol 46: 353-372, 2006.

42. Wang X, Yu T, Liao X, Yang C, Han C, Zhu G, Huang K, Yu L, Qin W, Su H, et al: The prognostic value of CYP2C subfamily genes in hepatocellular carcinoma. Cancer Med 7: 966-980, 2018.

43. Gelboin HV and Krausk P: Monoclonal antibodies and multifunctional cytochrome P450: Drug metabolism as paradigm. J Clin Pharmacol 46: 353-372, 2006.

44. Goldstein JA and de Morais SM: Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4: 285-299, 1994.

45. Hamman MA, Thompson GA and Hall SD: Regionselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C9. Biochem Pharmacol 68: 312-325, 2004.

46. Chang TK: Contribution of CYP2C9, CYP2A6, and CYP2B6 to the metabolism of ibuprofen and its active metabolites. J Clin Pharmacol 46: 353-372, 2006.
48. Yu D, Green B, Marrone A, Guo Y, Kadlubar S, Lin D, Fuscoe J, Pogribny I and Ning B: Suppression of CYP2C9 by microRNA hsa-miR-128-3p in human liver cells and association with hepatocellular carcinoma. Sci Rep 5: 8354, 2015.

49. Wang J, Greene S, Eriksson LC, Reinhner E, Reinhner E, Einarsson C, Eggersen G and Gäfvels M: Human sterol 12a-hydroxylase (CYP8B1) is mainly expressed in hepatocytes in a homogenous pattern. Histochem Cell Biol 123: 441-446, 2005.

50. Björkhem I and Eggersen G: Genes involved in initial steps of bile acid synthesis. Curr Opin Lipidol 12: 97-103, 2001.

51. Xu Y, Li F, Zalzala M, Xu J, Gonzalez FJ, Adorini L, Lee YK, Yin L and Zhang Y: Farnesoid X receptor activation increases cholesterol absorption in mice. Hepatology 64: 1072‑1085, 2016.

52. White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S, Fujimoto Y, Itabe H, Sakai J, Makita M, Noda J, Mori M, Higashi Y, Fujimoto K, Kojima S and Takano T: Identification of major proteins in the lipid droplet‑enriched fraction isolated from the human hepatocyte cell line HuH7. Biochim Biophys Acta 1644: 47‑59, 2004.

53. Singh O, Chan JY, Lin K, Heng CC and Chowbay B: SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia. PLoS One 7: e51771, 2012.

54. Rulcova A, Krausova L, Smutny T, Vrzal R, Dvorak Z, Jover R and Pavek P: Glucocorticoid receptor regulates organic cation transporter 1 (OCT1, SLC22A1) expression via HNF4α upregulation in primary human hepatocytes. Pharmacol Rep 65: 1322‑1335, 2013.

55. Herrera E, Lozano E, Macias RI, Vaquero J, Bujanda L, Banales JM, Marin JJ and Briz O: Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. Hepatology 58: 1065‑1073, 2013.